Alexion’s president to retire

Mr Keiser’s responsibilities will be distributed among current members of Alexion’s senior management reporting to Leonard Bell, CEO of Alexion. Mr Keiser will remain on Alexion’s board of directors at least through the expiration of his current term in 2009 and will be available to consult with management and the board in the future.

Mr Keiser, a co-founder of Alexion, played a central role in the commercial launch of Soliris in the US and Europe, and helped to build a broad platform for continued growth in those and other territories, the company said.

In addition to his work at Alexion, Mr Keiser has been active in various industry organizations and community activities and he will pursue these and other personal interests in retirement.

Mr Bell said: “David is a unique individual and executive and I have enjoyed working with him as Alexion built its global organization. His top-level expertise and broad experience were instrumental in our evolution from the early group of scientists into an international organization that is now able to deliver Soliris to a growing number of patients in a growing number of countries.”